The Top 3 Preclinical Considerations in the Discovery and Development of Novel Oncology Therapeutics

Andrea Charles

In this interview Kenneth J. Olivier Jr., PhD, Director of Toxicology at Merrimack Pharmaceuticals, speaks to Andrea Charles from Pharma IQ, about what trends he is witnessing in the improvement of safety assessments, his top 3 preclinical considerations in the discovery and development of novel oncology therapeutics and the implications and future considerations for use of computational biology in clinical drug development. [inlinead]...
To continue reading this story get free access